HARMONY

Healthcare alliance for resourceful medicines offensive against neoplasms in hematology
HARMONY logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 6
Grant agreement number
116026

Contributions
IMI Funding
20 200 000
EFPIA in kind
19 094 265
Other
451 352
Total Cost39 745 617

Summary

Blood cancers, or haematologic cancers (e.g. leukaemia, lymphoma and myeloma), affect the production and function of blood cells and account for about one third of cancer cases in children and about one third of cancer deaths. As many blood cancers are rare, and healthcare practice varies across EU, a lack of data on relevant outcomes represents a challenge for clinicians, researchers, and decision-makers alike. The HARMONY project aims to use ‘big data’ to deliver information that will help to improve the care of patients with these diseases. Specifically, the project will gather together, integrate and analyse anonymous patient data from a number of high quality sources. This will help the team to define clinical endpoints and outcomes for these diseases that are recognised by all key stakeholders. Meanwhile the project’s data sharing platform will facilitate and improve decision making for policy makers and clinicians alike to help them to give the right treatment to the right patient at the right time. More broadly, the project will result in a pan-European network of stakeholders with expertise in this disease area.

The project is part of IMI’s Big Data for Better Outcomes programme, which aims to facilitate the use of diverse data sources to deliver results that reflect health outcomes of treatments that are meaningful for patients, clinicians, regulators, researchers, healthcare decision-makers, and others.

Participants Show participants on map

EFPIA companies
  • Amgen NV, Brussels, Belgium
  • Bayer AG, Berlin, Germany
  • Celgene International II Sarl, Couvet, Switzerland
  • Janssen Pharmaceutica NV, Beerse, Belgium
  • Menarini Ricerche S.p.A., Pomezia, Italy
  • Novartis Pharma AG, Basel, Switzerland
  • Takeda Development Centre Europe Ltd., London, United Kingdom
Universities, research organisations, public bodies, non-profit groups
  • Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain
  • Alma Mater Studiorum - Università di Bologna, Bologna, Italy
  • Barts and the London NHS Trust, London, United Kingdom
  • Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany
  • ELN Foundation, Weinheim, Germany
  • Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
  • European Alliance for Personalised Medicine, Brussels, Belgium
  • European Hematology Association, The Hague, Netherlands
  • European Organisation for Research and Treatment of Cancer, Brussels, Belgium
  • European Research Initiative on CLL e.v., Köln, Germany
  • European Society for Blood and Marrow Transplantation, Leiden, Netherlands
  • Fondazione Italiana per lo studio delle sindromi mielodisplastiche onlus, Alessandria, Italy
  • Fundacio Privada Institut D’Investigacio Oncologica De Vall-Hebron, Barcelona, Spain
  • Fundacion Para La Investigacion Del Hospital Universitario La Fe De La Comunidad Valenciana, Valencia, Spain
  • Fundació Institut de Recerca Contra la Leucemia Josep Carreras, Barcelona, Spain
  • Fundación Instituto De Estudios De Ciencias De La Salud De Castilla Y Leon, Soria, Spain
  • Genome Research Limited, London, United Kingdom
  • German Society Pediatric Oncology Hematology GmbH gemeinnützig, Hannover, Germany
  • Groupe Francophone des Myélodysplasies, Paris, France
  • Group for Research on Adult Acute Lymphoblastic Leukemia, Pierre-Bénite, France
  • Heinrich-Heine-Universitaet Duesseldorf, Düsseldorf, Germany
  • Hôpital de la Salpêtrière, Paris , France
  • Johann Wolfgang Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany
  • LeukaNET e.V. , Riemerling, Germany
  • Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany
  • Masaryk University, Brno, Czech Republic
  • Medizinische Universitaet Wien, Vienna, Austria
  • National Institute for Health and Care Excellence, Manchester, United Kingdom
  • Ospedale Pediatrico Bambino Gesù, Rome, Italy
  • STICHTING VUmc, Amsterdam, Netherlands
  • The Lymphoma Study Association, Pierre Benite, France
  • Universita Degli Studi Di Torino, Turin, Italy
  • Universitaet Ulm, Ulm, Germany
  • University of Cambridge, Cambridge, United Kingdom
  • University of Helsinki, University of Helsinki, Helsinki, Finland
  • University of Navarra, Pamplona, Spain
  • University of York, York, United Kingdom
  • Università degli Studi di Roma "Tor Vergata", Rome, Italy
  • Univesity of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
  • Vib, Zwijnaarde - Gent, Belgium
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • GMV Soluciones Globales Internet S.A.U., Tres Cantos, Spain
  • MLL Munich Leukemia Laboratory GmbH, Munich, Germany
  • MediSapiens Oy, Helsinki, Finland
  • Synapse Research Management Partners S.L, Barcelona, Spain
Third parties
  • LYSARC The Lymphoma Academic Research Organisation, Pierre-Benite, France

CONTACT

Project coordinator
Jesus Maria Hernandez Rivas
FUNDACIÓN INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON
0034923210960
beniroc[at]usal.es
Project contact
Harmonyoffice[at]ibsal.es
Industry project leader
Dr. Patricia van Dijck, MD
Novartis Farma S.p.A.
Italy